FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379332922> ?p ?o ?g. }

• W4379332922 endingPage "e15131" @default.
• W4379332922 startingPage "e15131" @default.
• W4379332922 abstract "e15131 Background: Elimusertib is a highly selective oral inhibitor of the Ataxia telangiectasia and Rad3 related (ATR) kinase, which is required for efficient end-joining repair of double-stranded breaks, particularly during DNA replication. Many pediatric cancers involve potential ATR susceptibilities such as increased replication stress due to oncogenic fusions, specific DNA damage repair (DDR) deficiencies, oncogenic activation of DNA damage and nucleases such as PGBD5, as well as alternative lengthening of telomeres. We report the initial phase 1 results of PEPN2112 (NCT05071209), an ongoing pediatric phase 1/2 clinical trial of elimusertib monotherapy. Methods: Eligible patients (pts) included children, adolescents, and young adults with relapsed or refractory tumors with: (1) Ewing sarcoma or related EWSR1 fusion positive tumors (EWS), (2) alveolar rhabdomyosarcoma, PAX3-FOXO1 fusion positive (aRMS), or (3) non-CNS primary tumors exhibiting specific DDR pathway defects anticipated to sensitize to ATR inhibition. For pts < 18 years (yrs), a rolling-six design was used to evaluate elimusertib administered BID x3 days/week of a 28-day cycle starting at the adult equivalent recommended phase 2 dose (RP2D) of 24 mg/m 2 /dose (max 40 mg) with a potential de-escalation to 18 mg/m 2 /dose (max 30 mg). The pediatric RP2D determination was based upon dose limiting toxicity (DLT) criteria (CTCAEv5) during cycle 1. Pharmacokinetic (PK) studies were performed. Pts > 18 yrs could enroll onto the phase 2 cohorts at the adult RP2D simultaneously with the pediatric phase 1. Once the pediatric RP2D was defined, pts < 18 yrs accrued to the phase 2 cohorts and a PK expansion for pts < 12 yrs was opened. Results: 8 eligible pts were enrolled (4 males) on the phase 1 part of the study. 2 pts were inevaluable for DLT as they received < 75% of protocol therapy. Median (range) age was 13 (10-17) yrs. Diagnoses included: EWS (n = 4) and 1 pt each with aRMS, adrenocortical carcinoma, clear cell sarcoma, and osteosarcoma. At 24 mg/m 2 /dose, no DLTs were observed. Toxicities were hematologic, with grade 3 toxicities including anemia (n = 3), neutropenia (n = 4), and decreased white blood cells (n = 1). One pt experienced grade 4 lymphopenia. There were no grade 3/4 non-hematologic toxicities. Day 1 mean ± SD values of T max , C max , AUC 0-8h and t 1/2 were 1.6 ± 0.5 h, 1532 ± 385 ng/mL, 5863 ± 1841 h*ng/mL and 3.6 ± 0.9 h, respectively. Conclusions: Elimusertib-related toxicities were primarily hematologic. The RP2D for elimusertib monotherapy in pediatric pts is 24 mg/m 2 /dose (max 40 mg) orally BID x3 days/week continuously, analogous to dosing in adults with similar PK. Phase 2 and PK expansion cohorts as well as pharmacodynamic studies are ongoing. Clinical trial information: NCT05071209 ." @default.
• W4379332922 created "2023-06-05" @default.
• W4379332922 creator A5001064400 @default.
• W4379332922 creator A5007563936 @default.
• W4379332922 creator A5027416118 @default.
• W4379332922 creator A5032126905 @default.
• W4379332922 creator A5046068707 @default.
• W4379332922 creator A5046174386 @default.
• W4379332922 creator A5050571054 @default.
• W4379332922 creator A5050738935 @default.
• W4379332922 creator A5051652369 @default.
• W4379332922 creator A5055053315 @default.
• W4379332922 creator A5058354009 @default.
• W4379332922 creator A5062090005 @default.
• W4379332922 creator A5083681305 @default.
• W4379332922 date "2023-06-01" @default.
• W4379332922 modified "2023-09-26" @default.
• W4379332922 title "A phase 1/2 study of bay 18953444 (Elimusertib) in pediatric patients with relapsed or refractory solid tumors: Initial report of the phase 1 results of PEPN2112." @default.
• W4379332922 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e15131" @default.
• W4379332922 hasPublicationYear "2023" @default.
• W4379332922 type Work @default.
• W4379332922 citedByCount "0" @default.
• W4379332922 crossrefType "journal-article" @default.
• W4379332922 hasAuthorship W4379332922A5001064400 @default.
• W4379332922 hasAuthorship W4379332922A5007563936 @default.
• W4379332922 hasAuthorship W4379332922A5027416118 @default.
• W4379332922 hasAuthorship W4379332922A5032126905 @default.
• W4379332922 hasAuthorship W4379332922A5046068707 @default.
• W4379332922 hasAuthorship W4379332922A5046174386 @default.
• W4379332922 hasAuthorship W4379332922A5050571054 @default.
• W4379332922 hasAuthorship W4379332922A5050738935 @default.
• W4379332922 hasAuthorship W4379332922A5051652369 @default.
• W4379332922 hasAuthorship W4379332922A5055053315 @default.
• W4379332922 hasAuthorship W4379332922A5058354009 @default.
• W4379332922 hasAuthorship W4379332922A5062090005 @default.
• W4379332922 hasAuthorship W4379332922A5083681305 @default.
• W4379332922 hasConcept C112705442 @default.
• W4379332922 hasConcept C121332964 @default.
• W4379332922 hasConcept C121608353 @default.
• W4379332922 hasConcept C126322002 @default.
• W4379332922 hasConcept C142424586 @default.
• W4379332922 hasConcept C142724271 @default.
• W4379332922 hasConcept C143998085 @default.
• W4379332922 hasConcept C2778256501 @default.
• W4379332922 hasConcept C2780844630 @default.
• W4379332922 hasConcept C2993561819 @default.
• W4379332922 hasConcept C71924100 @default.
• W4379332922 hasConcept C87355193 @default.
• W4379332922 hasConceptScore W4379332922C112705442 @default.
• W4379332922 hasConceptScore W4379332922C121332964 @default.
• W4379332922 hasConceptScore W4379332922C121608353 @default.
• W4379332922 hasConceptScore W4379332922C126322002 @default.
• W4379332922 hasConceptScore W4379332922C142424586 @default.
• W4379332922 hasConceptScore W4379332922C142724271 @default.
• W4379332922 hasConceptScore W4379332922C143998085 @default.
• W4379332922 hasConceptScore W4379332922C2778256501 @default.
• W4379332922 hasConceptScore W4379332922C2780844630 @default.
• W4379332922 hasConceptScore W4379332922C2993561819 @default.
• W4379332922 hasConceptScore W4379332922C71924100 @default.
• W4379332922 hasConceptScore W4379332922C87355193 @default.
• W4379332922 hasFunder F4320332161 @default.
• W4379332922 hasIssue "16_suppl" @default.
• W4379332922 hasLocation W43793329221 @default.
• W4379332922 hasOpenAccess W4379332922 @default.
• W4379332922 hasPrimaryLocation W43793329221 @default.
• W4379332922 hasRelatedWork W2030363482 @default.
• W4379332922 hasRelatedWork W2523222294 @default.
• W4379332922 hasRelatedWork W2904856500 @default.
• W4379332922 hasRelatedWork W2912456485 @default.
• W4379332922 hasRelatedWork W2969533880 @default.
• W4379332922 hasRelatedWork W3083761066 @default.
• W4379332922 hasRelatedWork W4282959511 @default.
• W4379332922 hasRelatedWork W4285082525 @default.
• W4379332922 hasRelatedWork W4361953045 @default.
• W4379332922 hasRelatedWork W4361959752 @default.
• W4379332922 hasVolume "41" @default.
• W4379332922 isParatext "false" @default.
• W4379332922 isRetracted "false" @default.
• W4379332922 workType "article" @default.